Skip to content

Effect of dexmedetomidine on cognitive function in male patients undergoing video-assisted thoracoscopic surgery

Effect of dexmedetomidine on cognitive function in male patients undergoing video-assisted thoracoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17010958
Enrollment
Unknown
Registered
2017-03-23
Start date
2017-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

dexmedetomidine group:dexmedetomidine
Control:Placebo

Sponsors

The First Affiliated Hospital of Inner Mongolia Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Selected patients with thoracoscopic lobectomy for epidural anesthesia combined with general anesthesia, and the operative time are 2-4 hours; 2. aged more than 65 years old, male, ASA grade I or II , body mass index (BMI) 18-24kg/m2; 3. According to the disease history, physical examination, laboratory examination, no serious heart and lung, liver and kidney disease, no signs of difficult intubation, no obvious mental disorders and sedative hypnotic drug use history; 4. Preoperative cognitive function was normal.

Exclusion criteria

Exclusion criteria: 1. In the past, there were mental diseases, nervous system diseases, traumatic brain injury and mental disorders; 2. Patients with preoperative cognitive impairment or cognitive factors that have an effect on cognitive function; 3. Disturbance of acid-base balance of water and electrolyte, abnormal coagulation, the existence of epidural anesthesia contraindications; 4. The sedative hypnotic drugs and substance abuse, Parkinson's disease, alcoholism, alcohol or drug addiction; 5. There is a serious diseases of heart, lung, liver and kidney dysfunction and immune system diseases, endocrine immune system or may interfere with the results of any other disease or pathology; 6. The existence of serious vision, hearing or language barrier to complete the test of patients; 7. The known hypersensitivity to drug research.

Design outcomes

Primary

MeasureTime frame
BIS;BIS;SR;IL-1ß;TNF-a;S100ß;

Countries

China

Contacts

Public ContactShi Haixia

The First Affiliated Hospital of Inner Mongolia Medical University

haixia0403@163.com+86 15024969466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026